| 國立成功大學 |
2023 |
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
|
Hartmaier, R.J.;Markovets, A.A.;Ahn, M.J.;Sequist, L.V.;Han, J.-Y.;Cho, B.C.;Yu, H.A.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.-S.;Su, W.-C.;Kowalski, D.M.;Orlov, S.;Ren, S.;Frewer, P.;Ou, X.;Cross, D.A.E.;Kurian, N.;Cantarini, M.;J�nne, P.A. |
| 臺大學術典藏 |
2021-04-23T05:56:31Z |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist L.V.;Han J.-Y.;Ahn M.-J.;Cho B.C.;Yu H.;Kim S.-W.;Chih-Hsin Yang;Lee J.S.;Su W.-C.;Kowalski D.;Orlov S.;Cantarini M.;Verheijen R.B.;Mellemgaard A.;Ottesen L.;Frewer P.;Ou X.;Oxnard G.; Sequist L.V.; Han J.-Y.; Ahn M.-J.; Cho B.C.; Yu H.; Kim S.-W.; CHIH-HSIN YANG; Lee J.S.; Su W.-C.; Kowalski D.; Orlov S.; Cantarini M.; Verheijen R.B.; Mellemgaard A.; Ottesen L.; Frewer P.; Ou X.; Oxnard G. |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
|
Ranson M.;Ghiorghiu S;Dickinson P.A;Brown K.H;Cantarini M;Frewer P;Kim J.-H;Felip E;Haggstrom D;Horn L;Su W.-C;Kim S.-W;Ahn M.-J;Ramalingam S.S;Ohe Y;Planchard D;Kim D.-W;Chih-Hsin Yang;J?nne P.A; Jänne P.A; Chih-Hsin CHIH-HSIN YANG; Kim D.-W; Planchard D; Ohe Y; Ramalingam S.S; Ahn M.-J; Kim S.-W; Su W.-C; Horn L; Haggstrom D; Felip E; Kim J.-H; Frewer P; Cantarini M; Brown K.H; Dickinson P.A; Ghiorghiu S; Ranson M. |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
|
Ranson M.;Ghiorghiu S;Dickinson P.A;Brown K.H;Cantarini M;Frewer P;Kim J.-H;Felip E;Haggstrom D;Horn L;Su W.-C;Kim S.-W;Ahn M.-J;Ramalingam S.S;Ohe Y;Planchard D;Kim D.-W;Chih-Hsin Yang;J?nne P.A; Jänne P.A; Chih-Hsin CHIH-HSIN YANG; Kim D.-W; Planchard D; Ohe Y; Ramalingam S.S; Ahn M.-J; Kim S.-W; Su W.-C; Horn L; Haggstrom D; Felip E; Kim J.-H; Frewer P; Cantarini M; Brown K.H; Dickinson P.A; Ghiorghiu S; Ranson M. |
| 臺大學術典藏 |
2020-05-26T09:26:46Z |
135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC
|
J?nne P.;Chih-Hsin Yang;Barrett C;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; Barrett C; CHIH-HSIN YANG; Jänne P. |
| 臺大學術典藏 |
2020-05-26T09:26:46Z |
135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC
|
J?nne P.;Chih-Hsin Yang;Barrett C;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; Barrett C; CHIH-HSIN YANG; Jänne P. |
| 臺大學術典藏 |
2020-05-26T09:26:46Z |
134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC)
|
Mitsudomi T.;J?nne P;Cantarini M;Lawrance R;Weston S;Patel S;Yu K;Ramalingam S;Chih-Hsin Yang;Jenkins S; Jenkins S; CHIH-HSIN YANG; Ramalingam S; Yu K; Patel S; Weston S; Lawrance R; Cantarini M; Jänne P; Mitsudomi T. |
| 臺大學術典藏 |
2020-05-26T09:26:46Z |
134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC)
|
Mitsudomi T.;J?nne P;Cantarini M;Lawrance R;Weston S;Patel S;Yu K;Ramalingam S;Chih-Hsin Yang;Jenkins S; Jenkins S; CHIH-HSIN YANG; Ramalingam S; Yu K; Patel S; Weston S; Lawrance R; Cantarini M; Jänne P; Mitsudomi T. |
| 臺大學術典藏 |
2020-05-26T09:26:45Z |
LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results
|
Mitsudomi T.;Cantarini M;J?nne P.A;Ramalingam S.S;Chih-Hsin Yang; CHIH-HSIN YANG; Ramalingam S.S; Jänne P.A; Cantarini M; Mitsudomi T. |
| 臺大學術典藏 |
2020-05-26T09:26:45Z |
LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results
|
Mitsudomi T.;Cantarini M;J?nne P.A;Ramalingam S.S;Chih-Hsin Yang; CHIH-HSIN YANG; Ramalingam S.S; Jänne P.A; Cantarini M; Mitsudomi T. |
